Continentalic acid

Synonyms: 长白楤木酸
Continentalic acid 是一种二萜类有机酸,具有抗炎、抗氧化、神经保护、抗菌和抗肿瘤等多种活性,可减轻氧化应激、减少促炎细胞因子生成、抑制 MAPK 磷酸化和中性粒细胞浸润,并诱导癌细胞生长抑制和凋亡 (apoptosis),可用于创伤性脑损伤、癌症、炎症以及感染的相关研究。
产品编号: MS-M32376 纯度: 99.72% CAS No.: 19889-23-7 分子式: C20H30O2 分子量: 302.45
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价

产品描述

Continentalic acid 是一种二萜类有机酸,具有抗炎、抗氧化、神经保护、抗菌和抗肿瘤等多种活性,可减轻氧化应激、减少促炎细胞因子生成、抑制 MAPK 磷酸化和中性粒细胞浸润,并诱导癌细胞生长抑制和凋亡 (apoptosis),可用于创伤性脑损伤、癌症、炎症以及感染的相关研究。

生物实验数据

生物活性 Continentalic acid is a diterpenoid organic acid that exhibits multiple activities including anti-inflammatory, antioxidant, neuroprotective, antibacterial, and antitumor effects; it can attenuate oxidative stress, reduce pro-inflammatory cytokine production, inhibit MAPK phosphorylation and neutrophil infiltration, and induce cancer cell growth inhibition and apoptosis, making it applicable for research related to traumatic brain injury, cancer, inflammation, and infection.
体外研究
(In Vitro)

Continentalic acid (10-100 μM; 24-72 h) 可呈时间和剂量依赖性抑制人肝癌 HepG2 细胞的生长,其 IC50 为 50 μM。
Continentalic acid (25-100 μM; 72 h) 可诱导人肝癌 HepG2 细胞发生凋亡,包括形态学改变、DNA 片段化。
Continentalic acid (10-100 μM; 48 h) 可在调控人肝癌 HepG2 细胞中凋亡相关蛋白的表达,上调 caspase-3、Bak 和 Bax 的水平,诱导 PARP 裂解,并下调 Bcl-2 的水平。
Continentalic acid (1-20 μM) 可剂量依赖性地抑制人骨关节炎软骨细胞中 IL-1β 刺激的 IL-6、IL-8、MMP-13、COX-2 和 PGE2 的产生。
Continentalic acid (1-20 μM; 24 h) 呈剂量依赖性地抑制经 IL-1β 刺激的人骨关节炎软骨细胞中 p38、ERK1/2 和 JNK 丝裂原活化蛋白激酶 (MAP 激酶) 的磷酸化。
Continentalic acid (10 μM) 可在孵育 1 h 后抑制 IL-1β 诱导的人骨关节炎软骨细胞中 NF-κB/p65 的核转位。
Continentalic acid (8-16 µg/mL; 24 h) 可强效抑制甲氧西林敏感金黄色葡萄球菌 ATCC 25923、甲氧西林耐药金黄色葡萄球菌 ATCC 33591 以及 12 株临床耐甲氧西林金黄色葡萄球菌 (MRSA) 分离株的生长,其 MIC 值为 8-16 µg/mL。

Apoptosis Analysis

Cell Line: human hepatocarcinoma HepG2 cells
Concentration: 10, 25, 50, 100 μM
Incubation Time: 72 h
Result: Induced distinct apoptotic morphological changes in HepG2 cells by 72 h, including cell shrinkage, nuclear and cytoplasmic condensation, chromatin condensation, and polylobation or fragmentation of nuclei.
Caused visible apoptotic changes in cells treated with 25, 50, and 100 μM continentalic acid.\nInduced dose-dependent DNA ladder formation in HepG2 cells after 72 h of incubation.
Caused clear laddering observed at concentrations of 25, 50, and 100 μM.

Western Blot Analysis

Cell Line: IL-1β-stimulated human osteoarthritis (OA) chondrocytes
Concentration: 1, 3, 5, 10, 20 μM
Incubation Time: 24 h
Result: Significantly inhibited IL-1β-stimulated phosphorylation of p38, ERK1/2, and JNK protein kinases in a dose-dependent manner.
体内研究
(In Vivo)

Continentalic acid (10-100 mg/kg;腹腔注射;LPS 处理前 30 分钟单次给药) 对 LPS (MS-X54539) 诱导的 BALB/c 小鼠急性肺损伤表现出剂量依赖性保护作用。
Continentalic acid (0.97 mg/kg;腹腔注射;每日 1 次;连续 30 天) 在 MIA 诱导的骨关节炎大鼠中表现出显著的抗关节炎功效,可恢复负重平衡并防止软骨损伤和蛋白聚糖丢失。
Continentalic acid (1-50 mg/kg;腹腔注射;每日 1 次,连续 14 天) 在小鼠创伤性脑损伤 (TBI) 模型中发挥强效神经保护活性。

Animal Model: BALB/c mice (6-week-old male, 27-33 g, traumatic brain injury weight-drop model)
Dosage: 1 mg/kg; 10 mg/kg; 50 mg/kg
Administration: i.p.; daily; 14 days
Result: Reduced neurological severity score.
Restored paw withdrawal threshold.
Reduced cortical histopathological damage, increased neuronal count, and reduced cerebral microbleeds compared to the TBI group.
Downregulated mRNA and protein expression of GFAP, Iba1, TLR4, NF-κB, and cleaved caspase-3; upregulated mRNA and protein expression of IκB-α and Bcl-2 compared to the TBI group.
Reduced TBI-induced DNA damage compared to the TBI group.
Reduced levels of NO, LPO, IL-1β, and TNF-α; increased levels of GST, GSH, catalase, and SOD compared to the TBI group.
Animal Model: BALB/c (male, 3-4 weeks old, 22-26 g, LPS-induced acute lung injury)
Dosage: 10 mg/kg; 50 mg/kg; 100 mg/kg
Administration: i.p.; single dose 30 minutes pre-LPS
Result: Achieved an 80% 24-hour survival rate at 100 mg/kg (vs. 20% in LPS-only group); showed no protective effect on mortality at 10 mg/kg.
Significantly reduced LPS-induced pyrexia at 50 mg/kg and 100 mg/kg).
Reduced lung wet/dry ratio dose-dependently at all three doses, with marked inhibition at 100 mg/kg.
Significantly elevated lung tissue levels of GSH, GST, catalase, and SOD at all three doses, with largest increases at 100 mg/kg.
Significantly reduced lung tissue MDA levels and both plasma and lung tissue NO levels at all three doses, with effects increasing with dose.
Significantly inhibited LPS-induced increases in lung tissue IL-1β, IL-6, and TNF-α at all three doses.
Normalized total neutrophil counts (NEU) to near control levels at 50 mg/kg and 100 mg/kg; normalized WBC counts to control levels at 100 mg/kg.
Reduced lung injury scores dose-dependently; reduced neutrophilic infiltration and improved tracheal architecture at these doses.
Reduced lung tissue MPO activity at all three doses, with significant inhibition at 100 mg/kg.
Significantly reduced lung tissue iNOS expression and significantly increased Nrf2 protein expression at 100 mg/kg.
性状 固体
颜色 White to off-white

化学信息

分子量 302.45
分子式 C20H30O2
CAS No. 19889-23-7
别名 长白楤木酸

储存&溶解度

储存方式

4°C, protect from light

*In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (330.63 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM3.3063 mL16.5317 mL33.0633 mL82.6583 mL
5 mM0.6613 mL3.3063 mL6.6127 mL16.5317 mL
10 mM0.3306 mL1.6532 mL3.3063 mL8.2658 mL
15 mM0.2204 mL1.1021 mL2.2042 mL5.5106 mL
20 mM0.1653 mL0.8266 mL1.6532 mL4.1329 mL
25 mM0.1323 mL0.6613 mL1.3225 mL3.3063 mL
30 mM0.1102 mL0.5511 mL1.1021 mL2.7553 mL
40 mM0.0827 mL0.4133 mL0.8266 mL2.0665 mL
50 mM0.0661 mL0.3306 mL0.6613 mL1.6532 mL
60 mM0.0551 mL0.2755 mL0.5511 mL1.3776 mL
80 mM0.0413 mL0.2066 mL0.4133 mL1.0332 mL
100 mM0.0331 mL0.1653 mL0.3306 mL0.8266 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础